Dinaciclib
Dinaciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cyclin-dependent kinase 9, cyclin-dependent kinase 1, cyclin-dependent kinase 2, and cyclin-dependent kinase 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 2 | 1 | — | — | 5 |
| Leukemia | D007938 | — | C95 | 2 | 1 | 1 | — | — | 3 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | 1 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 3 | 1 | — | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 1 | 2 | — | — | — | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 1 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dinaciclib |
| INN | dinaciclib |
| Description | 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol is a pyrazolopyrimidine. |
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12 |
Identifiers
| PDB | — |
| CAS-ID | 779353-01-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103840 |
| ChEBI ID | — |
| PubChem CID | 46926350 |
| DrugBank | DB12021 |
| UNII ID | 4V8ECV0NBQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CDK9
CDK9
CDK1
CDK1
CDK2
CDK2
CDK5
CDK5
Organism
Homo sapiens
Gene name
CDK9
Gene synonyms
CDC2L4, TAK
NCBI Gene ID
Protein name
cyclin-dependent kinase 9
Protein synonyms
C-2K, CDC2-related kinase, Cell division cycle 2-like protein kinase 4, Cell division protein kinase 9, serine/threonine protein kinase PITALRE, Serine/threonine-protein kinase PITALRE, Tat-associated kinase complex catalytic subunit
Uniprot ID
Mouse ortholog
Cdk9 (107951)
cyclin-dependent kinase 9 (Q99J95)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,068 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use